DNTH vs EYPT: fair value comparison
Dianthus Therapeutics, Inc. and EyePoint, Inc. · Updated 2026-10-19
DNTH has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. EYPT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, DNTH currently ranks higher by quality score.
| DNTH | EYPT | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $72.09 | $2.99 |
| 12-month range | $32.92–$115.96 | $2.99–$18.85 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #185 of 301 Healthcare | #186 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | Contracting |
| Revenue growth | Declining | Declining |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: DNTH fair value analysis · EYPT fair value analysis